<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>辉瑞生物科技疫苗可能比你想象的有效得多</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">辉瑞生物科技疫苗可能比你想象的有效得多</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-11-12 03:24:23</div><div class="page_narrow text-break page_content"><p>tl;dr; The point estimate for vaccine effectiveness may be 97%, which is a lot higher than 90%</p><p>疫苗有效性的点估计值可能为97%，远高于90%。</p><p> Yesterday an announcement went out that the SARS-CoV-2 vaccine candidate developed by Pfizer and Biontech was determined to be effective during an  interim analysis. This is fantastic news. Perhaps the best news of the year. It is however another example of science via press release. There is very limited information contained in the press release and one can only wonder why they couldn&#39;t take the time to write up a two page report for the scientific community.</p><p>昨天有消息称，辉瑞公司和BioNTech公司联合开发的SARS-CoV-2候选疫苗在中期分析中被确定为有效。这是个极好的消息。或许是今年最好的消息。然而，这是通过新闻稿展示科学的又一个例子。新闻稿中包含的信息非常有限，人们只能奇怪为什么他们不能花时间为科学界写一份两页的报告。</p><p> That said, we can draw some inferences from the release that may help put this in context. From the press release we know that a total of 94 COVID-19 cases were recorded.</p><p>这就是说，我们可以从发布中得出一些推论，这可能有助于理解这一点。从新闻稿中我们了解到，共有94名新冠肺炎案件被记录在案。</p><p> &#34;Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. &#34;</p><p>在这些讨论结束后，可评估的病例数达到94例，DMC对所有病例进行了第一次分析。&#34；</p><p> However, we don&#39;t know how many of these come from the control group, and how many come from the treatment group. We also don&#39;t know how many total subjects are in the treatment and control arms. We do get two important quotes regarding efficacy.</p><p>然而，我们不知道其中有多少来自对照组，有多少来自治疗组。我们也不知道总共有多少受试者在治疗和控制武器中。我们确实得到了两条关于疗效的重要引述。</p><p> &#34;Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis</p><p>在第一次中期疗效分析中发现，候选疫苗在无SARS-CoV-2感染证据的参与者中预防新冠肺炎的有效性超过90%。</p><p>  The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose.&#34;</p><p>接种疫苗的个人和接受安慰剂的人之间的病例分裂表明，在第二次接种后7天，疫苗有效率超过90%。</p><p> How should we interpret these? Was the observed rate of infection 90% lower in the treatment group, or are we to infer that the true (population parameter) efficacy is at least 90%? I would argue that the wording supports the later. If they were just providing a point estimate why express it as a bound? Why would they phrase it as &#34;indicates a vaccine efficacy rate above 90%&#34; if there was a reasonable probability that the actual vaccine efficacy rate is below 90%?</p><p>我们应该如何解读这些呢？观察组的感染率是否降低了90%，或者我们如何推断真正的(人口参数)疗效至少为90%？我会争辩说，措辞支持后者。如果他们只是提供一个点数估计，为什么要把它表示为一个界限呢？如果疫苗实际有效率有合理的概率低于90%，他们为什么要把它表述为疫苗有效率高于90%？</p><p> We can get some additional insight by looking at the  study design. It specifies how the interim analysis is to be done. Specifically on pages 102-103, it calls for a Bayesian analysis using a beta binomial model with a weakly-informative prior.</p><p>通过查看研究设计，我们可以获得一些额外的见解。它规定了如何进行中期分析。具体来说，在第102-103页，它要求使用带有弱信息先验的Beta二项式模型进行贝叶斯分析。</p><p> To me, the most compatible statistical translation of their press release is that we are sure with 95% probability that the vaccine&#39;s efficacy is greater than 90%. Why &#34;95% probability?&#34; Well, 95% probability intervals are standard for the medical literature if you are doing Bayesian analysis (deal with it), and 95% intervals with 2.5% probabilities on each tail are littered through the design document. They are going to the FDA with these claims, so they will likely stick to the standard evidentiary rules.</p><p>对我来说，最符合他们新闻稿的统计翻译是，我们以95%的概率确定疫苗的效力大于90%。为什么是95%的概率？嗯，如果你在做贝叶斯分析(处理它)，95%的概率区间是医学文献的标准区间，设计文档中散落着每条尾巴都有2.5%概率的95%的区间。他们将把这些指控提交给FDA，因此他们很可能会坚持标准的证据规则。</p><p> Assuming my interpretation is correct, let&#39;s back out how many cases were in the treatment group. Conditional on the total number of infections, the number of infections in the treatment group is distributed binomially. We apply the beta prior to this posterior and then transform our inferences from the binomial proportion to vaccine effectiveness. Vaccine effectiveness is one minus the infection rate ratio between the two groups, and the rate ratio is related to the binomial proportion as the odds.</p><p>假设我的解释是正确的，让我们回到治疗组中有多少病例。根据感染总数，治疗组感染人数呈二项分布。我们在此后验结果之前应用贝塔系数，然后将我们的推论从二项式比例转换为疫苗效力。疫苗的有效性是两组之间的感染率比减去1，而感染率比与二项式比例有关，作为赔率。</p><p>  &gt; # reference: https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf&gt; &gt; # prior interval (matches prior interval on page 103)&gt; qbeta(c(.025,.975),.700102,1)[1] 0.005148448 0.964483043&gt; &gt; &gt; # posterior&gt; cases_treatment &lt;- 3&gt; cases_control &lt;- 94 - cases_treatment&gt; theta_ci &lt;- qbeta(c(.025,.975),cases_treatment+.700102,cases_control+1)&gt; rate_ratio_ci &lt;- theta_ci / (1-theta_ci)&gt; &gt; # effectiveness&gt; 100 * (1 - rate_ratio_ci)[1] 98.98688 90.68447&gt; library(ggplot2)&gt; xx &lt;- (0:60)/500&gt; yy &lt;- sapply(xx, function(x) dbeta(x,cases_treatment+.700102,cases_control+1))&gt; xx &lt;- 100 * (1 - xx / (1 - xx))&gt; ggplot() + + geom_area(aes(x=xx,y=yy)) + + theme_bw() + + xlab(&#34;Vaccine Effectiveness&#34;) + + ylab(&#34;Posterior Density&#34;)</p><p>&gt；#参考：https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf&gt；&gt；#上一个间隔(与第103页上的前一个间隔匹配)&gt；Qbeta(c(.025，.975)，.700102，1)[1]0.005148448 0.964483043&gt；&gt；&gt；#后部&gt；Cases_Treatment&lt；-3&gt；Cases_Control&lt；-94-Cases_Treatment&gt；theta_ci&lt；-Qbeta(c(.025，.975)，Cases_Treatment+.700102，Cases_Control+1)&gt；rate_rate_ci&lt；-theta_ci/(1-theta_ci)&gt；&gt；#有效性&gt；100*(1-Rate_Ratio_Ci)[1]98.98688 90.68447&gt；库(Ggplot2)&gt；xx&lt；-(0：60)/500&gt；yy&lt；-sApply(xx，函数(X)dbeta(x，Cases_Treatment+.700102，Cases_Control+1))&gt；xx&lt；-100*(1-xx/(1-xx))&gt；gglot()++geom_area(aes(x=xx，y=yy))++Theme_BW()++xlab(&#34；疫苗有效性)++Ylab(&#34；后部密度&#34；)。</p><p>  The largest number of treatment cases that would have a lower bound greater than 90% is 3, corresponding to 91 cases in the control group. The estimated effectiveness of the vaccine is then 97% with a probability interval from 90.7% to 99.0%. So sure, the effectiveness could be 90% or so, but odds are that it is a  lot higher as the posterior plot below shows.</p><p>治疗下限大于90%的最大病例数为3例，相当于对照组91例。因此，疫苗的估计有效性为97%，概率区间为90.7%至99.0%。因此，可以肯定的是，有效率可能在90%左右，但可能性要高得多，如下面的后图所示。</p><p>  To put this in perspective, consider the rates at which a 97% effective vaccine fails to provide protection, leading to an infection. A 90% effective vaccine has a 3.3 times higher failure rate, so if you vaccinated a population with a 90% effective vaccine and everyone was exposed you&#39;d expect to see 3.3 times more infections compared to if you had used a 97% effective vaccine.</p><p>要正确看待这一点，请考虑97%有效疫苗未能提供保护并导致感染的比率。90%有效疫苗的失败率是97%有效疫苗的3.3倍，所以如果你给一个人群接种了90%有效疫苗，而每个人都接触了疫苗，那么你预计感染人数将是使用97%有效疫苗的人群的3.3倍。</p><p> I do note that the analysis plan calls for sequential stopping rules that preserve type I error; however, I don&#39;t believe that any reported statistics would be adjusted for that. Unlike frequentist intervals, Bayesian intervals are unchanged no matter how many interim analyses you do.</p><p>我确实注意到，分析计划要求使用顺序停止规则来保留第I类错误；然而，我不认为任何报告的统计数据会因此而进行调整。与频率区间不同，贝叶斯区间是不变的，无论你做多少中期分析。</p><p> There is a lot we don&#39;t know, and hopefully we will get more scientific clarity in the coming weeks. As it stands now, it seems like this vaccine has efficacy way above my baseline expectations, perhaps even in the 97% range or higher.</p><p>我们还有很多不知道的东西，希望在接下来的几周里我们会有更多的科学发现。目前看来，这种疫苗的效果似乎远远超出了我的基线预期，甚至可能在97%或更高的范围内。</p><p> I could be wrong in my interpretation of the press release, and they are in fact talking about the sample effectiveness rather than the true effectiveness. In that case, 8 of the 94 cases would have been in the treatment group, and the interval for the true effectiveness would be between 81.6% and 95.6%. The posterior distribution would look pretty darn good, but not quite as nice as the previous one.</p><p>我对新闻稿的理解可能是错误的，事实上，他们谈论的是样本效力，而不是真正的效力。在这种情况下，94例中有8例在治疗组中，真正有效的间隔在81.6%到95.6%之间。后验分布看起来相当不错，但没有前一次那么好。</p><p>  It is important to have realistic expectations though. Efficacy is not the only metric that is important in determining how useful the vaccine is. Due to the fact that the study population has only been followed for months, we do not know how long the vaccine provides protection for. There is significant evidence of COVID-19 reinfection, so the expectation is that a vaccine will not provide permanent immunity. If the length of immunity is very short (e.g. 3 months), then it won&#39;t be the silver bullet we are looking for. I&#39;d be happy to see a year of immunity and ecstatic if it lasts two.</p><p>不过，重要的是要有现实的期望。在决定疫苗的有效性方面，效力并不是唯一重要的衡量标准。由于研究人群只被跟踪了几个月，我们不知道疫苗能提供多长时间的保护。有重要证据表明新冠肺炎会再次感染，因此人们预计疫苗不会提供永久免疫力。如果豁免期很短(例如3个月)，那么它不会是我们正在寻找的灵丹妙药。如果能持续两年，我会很高兴看到这一年的豁免权和欣喜若狂。</p><p> Additionally, there are the side effects. We&#39;ll have to see what the results are from this trial, but in  the phase II trial, something like 8% or 17% of subjects (I&#39;m unsure of the dosage for the phase III) experienced a fever after their booster. It is likely that you&#39;ll want to take the day after you get the second shot off work in case you don&#39;t feel well. The rate of side effects may harm vaccine uptake.</p><p>此外，还有副作用。我们将不得不看看这项试验的结果，但在第二阶段试验中，大约8%或17%的受试者(我不确定第三阶段的剂量)在加强免疫后出现发烧。很可能你会想在第二次工作结束后休息一天，以防你感觉不舒服。副作用的发生率可能会损害疫苗的接种率。</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://blog.fellstat.com/?p=440">https://blog.fellstat.com/?p=440</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/生物科技/">#生物科技</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/biontech/">#biontech</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/美国/">#美国</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/linux/">#linux</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/程序/">#程序</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>